Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment

被引：5

作者：

Menges, Dominik ^{[1
]}

Piatti, Michela C. ^{[1
]}

Omlin, Aurelius ^{[2
,3
]}

Cathomas, Richard ^{[4
]}

Benamran, Daniel ^{[5
]}

Fischer, Stefanie ^{[2
]}

Iselin, Christophe ^{[5
]}

Kung, Marc ^{[6
]}

Lorch, Anja ^{[7
]}

Prause, Lukas ^{[8
]}

Rothermundt, Christian ^{[2
]}

Stern, Alix O'Meara ^{[9
]}

Zihler, Deborah ^{[10
]}

Lippuner, Max ^{[11
]}

Braun, Julia ^{[1
]}

Cerny, Thomas ^{[12
,13
]}

Puhan, Milo A. ^{[1
]}

机构：

[1] Univ Zurich, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland

[2] Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland

[3] Onkozentrum Zurich, Zurich, Switzerland

[4] Kantonsspital Graubunden, Div Oncol Hematol, Chur, Switzerland

[5] Hop Univ Geneve, Dept Urol, Geneva, Switzerland

[6] Hop Cantonal Fribourg, Dept Oncol, Fribourg, Switzerland

[7] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

[8] Kantonsspital Aarau, Dept Urol, Aarau, Switzerland

[9] Reseau Hosp Neuchatelois, Dept Oncol, Neuchatel, Switzerland

[10] Kantonsspital Aarau, Dept Oncol Hematol & Transfus Med, Aarau, Switzerland

[11] Europa Uomo Switzerland, Ehrendingen, Switzerland

[12] Fdn Board, Canc Res Switzerland, Bern, Switzerland

[13] Swissmedic, Human Med Expert Comm, Bern, Switzerland

来源：

EUROPEAN UROLOGY OPEN SCIENCE | 2023年 / 51卷

关键词：

Adverse effects; Benefit; Benefit-harm assessment; Discrete choice experiment; Harm; Metastasis; Patient-centered care; Patient preferences; Prostate cancer; Survival; Treatment; LIFE-CYCLE; INFORM; THERAPY; DESIGNS;

D O I：

10.1016/j.euros.2023.03.001

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Patient preferences for treatment outcomes are important to guide decision-making in clinical practice, but little is known about the preferences of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Objective: To evaluate patient preferences regarding the attributed benefits and harms of systemic treatments for mHSPC and preference heterogeneity between individuals and specific subgroups. Design, setting, and participants: We conducted an online discrete choice experiment (DCE) preference survey among 77 patients with metastatic prostate cancer (mPC) and 311 men from the general population in Switzerland between November 2021 and August 2022. Outcome measurements and statistical analysis: We evaluated preferences and preference heterogeneity related to survival benefits and treatment-related adverse effects using mixed multinomial logit models and estimated the maximum survival time participants were willing to trade to avert specific adverse effects. We further assessed characteristics associated with different preference patterns via subgroup and latent class analyses. Results and limitations: Patients with mPC showed an overall stronger preference for survival benefits in comparison to men from the general population (p = 0.004), with substantial preference heterogeneity between individuals within the two

引用

页码：26 / 38

页数：13

共 56 条

[1] Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force [J].

Bridges, John F. P. ;

Hauber, A. Brett ;

Marshall, Deborah ;

Lloyd, Andrew ;

Prosser, Lisa A. ;

Regier, Dean A. ;

Johnson, F. Reed ;

Mauskopf, Josephine .

VALUE IN HEALTH, 2011, 14 (04) :403-413

[2] Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study [J].

Burbridge, Claire ;

Randall, Jason A. ;

Lawson, Joe ;

Symonds, Tara ;

Dearden, Lindsay ;

Lopez-Gitlitz, Angela ;

Espina, Byron ;

McQuarrie, Kelly .

SUPPORTIVE CARE IN CANCER, 2020, 28 (07) :3093-3101

[3] Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis [J].

Burdett, Sarah ;

Boeve, Liselotte M. ;

Ingleby, Fiona C. ;

Fisher, David J. ;

Rydzewska, Larysa H. ;

Vale, Claire L. ;

van Andel, George ;

Clarke, Noel W. ;

Hulshof, Maarten C. ;

James, Nicholas D. ;

Parker, Christopher C. ;

Parmar, Mahesh K. ;

Sweeney, Christopher J. ;

Sydes, Matthew R. ;

Tombal, Bertrand ;

Verhagen, Paul C. ;

Tierney, Jayne F. .

EUROPEAN UROLOGY, 2019, 76 (01) :115-124

[4] Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK [J].

Catt, Susan ;

Matthews, Lucy ;

May, Shirley ;

Payne, Heather ;

Mason, Malcolm ;

Jenkins, Valerie .

EUROPEAN JOURNAL OF CANCER CARE, 2019, 28 (06)

[5] A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer [J].

Connor, Martin J. ;

Genie, Mesfin G. ;

Burns, David ;

Bass, Edward J. ;

Gonzalez, Michael ;

Sarwar, Naveed ;

Falconer, Alison ;

Mangar, Stephen ;

Dudderidge, Tim ;

Khoo, Vincent ;

Winkler, Mathias ;

Ahmed, Hashim U. ;

Watson, Verity .

EUROPEAN UROLOGY OPEN SCIENCE, 2022, 36 :9-18

[6] Men's preferences for prostate cancer screening: a discrete choice experiment [J].

de Bekker-Grob, E. W. ;

Rose, J. M. ;

Donkers, B. ;

Essink-Bot, M-L ;

Bangma, C. H. ;

Steyerberg, E. W. .

BRITISH JOURNAL OF CANCER, 2013, 108 (03) :533-541

[7] Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project [J].

de Bekker-Grob, Esther W. ;

Berlin, Conny ;

Levitan, Bennett ;

Raza, Karim ;

Christoforidi, Kalliopi ;

Cleemput, Irina ;

Pelouchova, Jana ;

Enzmann, Harald ;

Cook, Nigel ;

Hansson, Mats G. .

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2017, 10 (03) :263-266

[8] Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries [J].

de Freitas, Hayley M. ;

Ito, Tetsuro ;

Hadi, Monica ;

Al-Jassar, Gemma ;

Henry-Szatkowski, Mickael ;

Nafees, Beenish ;

Lloyd, Andrew J. .

ADVANCES IN THERAPY, 2019, 36 (02) :318-332

[9] Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer [J].

Dearden, Lindsay ;

Shalet, Natalie ;

Artenie, Cristiana ;

Mills, Andrew ;

Jackson, Claire ;

Grant, Laura ;

Gater, Adam .

EUROPEAN JOURNAL OF CANCER CARE, 2019, 28 (01)

[10] Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer - An interview study [J].

Doveson, Sandra ;

Holm, Maja ;

Axelsson, Lena ;

Fransson, Per ;

Wennman-Larsen, Agneta .

EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2020, 49

← 1 2 3 4 5 6 →